Skip to main content

Advertisement

Table 3 Clinical outcomes at 12th month in GLP-1 agonist users vs. never-GLP-1 agonist users

From: Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate

Study outcomes Overall population (n 559) GLP-1 agonist therapy (n 288) No GLP-1 agonist therapy (n 271) p value
All cause deaths (%) 35 (6.3) 19 (6.6) 16 (5.9) n.s.
Cardiac deaths (%) 28 (5.0) 15 (5.2) 13 (4.8) n.s.
Hospitalization for heart failure (%) 124 (22.2) 48 (16.7) 76 (28.0) < 0.05*
CRTd responders rate (%) 348 (62.2) 193 (67) 155 (57.2) < 0.05*
AF events n of events 64 23 41 < 0.05*
VT events n of events 135 55 75 < 0.05*
Stroke (%) 11 (2) 6 (2.1) 5 (1.8) n.s
ATP n of events 105 37 68 < 0.05*
CRTd shocks n of events 52 9 43 < 0.05*
Appropriate therapy n of events 112 74 38 < 0.05*
Inappropriate therapy n of events 43 12 21 < 0.05*
  1. AF: atrial fibrillation; VT: ventricular tachycardia; CRTd: cardiac resynchronization with a defibrillator; n: number